EMERGENT BIOSOLUTIONS INC. Proceeds from Sale of Productive Assets
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Sale of Productive Assets of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2021-02-19
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for the quarter ending 2019-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for the quarter ending 2019-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for the quarter ending 2018-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for the quarter ending 2018-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for fiscal 2020 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for fiscal 2018 was $2.60M.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of productive assets for fiscal 2017 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 6 month as first filed | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 9 month as first filed | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-19 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $0.00 derived: sum of 2 quarters · filed 2021-02-19 | $0.00 10-K · filed 2021-02-19 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-02 | |||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $0.00 derived: sum of 2 quarters · filed 2021-02-19 | $2.60M 10-K · filed 2021-02-19 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $2.60M 10-Q · filed 2019-11-07 | $2.62M 10-Q · filed 2018-11-02 | |||
| 2018-06-30 | $2.60M 10-Q · filed 2019-08-02 | $2.62M 10-Q · filed 2018-08-03 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $0.00 10-Q · filed 2018-11-02 | ||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | |||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |